

REQUEST FOR ASSISTANT DIRECTOR DECISION – ADD220

Title: Business Case for an International Dementia Research Institute

Executive Summary:

Dementia has been recognised by the G7 as one of the biggest global challenges of our time. The annual financial impact on the UK economy is £23bn. The GLA is championing a London based International Dementia Research Institute. The Institute will build on existing strengths in research and act as a facilitator for collaboration. To deliver this for London, Government backing must be secured with evidence provided from an independent expert in the business case for such a large investment. DD1217 stipulated that the recipient of the £50,000 grant to develop a business case would be UCL. This ADD proposes that the grant be made to MedCity as an independent expert. The change from UCL is to secure Government backing for the allocation of significant infrastructure funds as this will be done via competition and must not be biased to one potential host institution.

Decision:

The Assistant Director of Health and Communities approves grant funding of up to £50,000 to MedCity Limited for an independent analysis of the business case for an International Dementia Research Institute (noting a change from the approval in DD1217 to grant fund UCL Partners).

AUTHORISING ASSISTANT DIRECTOR/HEAD OF UNIT:

I have reviewed the request and am satisfied it is correct and consistent with the Mayor's plans and priorities.

It has my approval.

Name: Amanda Coyle

Position: Assistant Director Health and Communities

Signature:

Date: 4 September 2014

PART I - NON-CONFIDENTIAL FACTS AND ADVICE

Decision required – supporting report

1. Introduction and background

- 1.1 The Central Programme Panel approved the funds for this project on 20/05/14 and DD1217 approved expenditure of £50,000 on a business case for an International Dementia Research Institute.
- 1.2 By 2025, one million people in the UK and over 60 million globally will have dementia. This will have devastating consequences on the lives of affected people and their families, on social care needs, and for economic prosperity. The financial impact to the UK alone is estimated to be £23 billion annually, with 800,000 people living with the condition at an average cost of £29,746 per person per year, and a further £8 billion attributed to the value of work otherwise done by family carers (Alzheimer's Society, 2013). Population projections for London suggest a different demographic profile and this gives a 14% rise in the expected prevalence by 2021. Estimated public sector annual cost of services used by people with dementia aged 65 and over in London is £1bn (NHS Commissioning Support for London, 2011).
- 1.3 The UK has existing centres of world-class strength in dementia research, education and care, but no single centre has the complete array of talent, technology or expertise to address the dementia challenge alone. A new hub model is required that harnesses and coordinates the collective capability of our dementia research community, to deliver more than the sum of our parts and accelerate patient and economic benefit.
- 1.4 An International Dementia Research Institute will be a consortium which draws together into a collaborative hub the expertise in dementia research from across the UK to address the following key objectives:
 - a. To drive collaboration between academic centres in our research and clinical efforts, to build shared learning, avoid duplication and maximise return on public, charity and industry investment.
 - b. To provide a dedicated focus for education and capacity building and investment in the next generation;
 - c. To provide a clear and dedicated focus for industry collaboration in UK dementia research;
 - d. To act as point of contact and facilitator for international collaboration, working in partnership with the World Dementia Envoy to co-ordinate international efforts to support global dementia innovation.
- 1.5 The benefits of such a research site in London will strengthen London's position internationally as a hub for life science research. A fuller analysis is being sought with this project to qualify the other economic benefits such as added public and private research financing following a significant infrastructural investment.
- 1.6 DD1217 approved a grant of £50,000 for UCL to carry out this work. However, following feedback from stakeholders, including UCL and Government, it is deemed to critical that the business case is independently estimated and verified.
- 1.7 The £50,000 grant to MedCity will allow the resourcing of external experts to produce an independent business case. It will also leverage MedCity's own internal expertise.
- 1.8 This will be for the following activity

- Commission via an Invitation to Tender process an independent business case for the International Dementia Research Institute
- Manage the contract to produce the analysis in a report format
- Facilitate presentation of report to relevant industry stakeholder
- Deliver the business case in a report format to the GLA
- Support promotion of the business case with Government and other infrastructure investors

2. Objectives and expected outcomes

- 2.1 Government backing and capital investment is necessary to secure the new physical facility of an International Dementia Research Institute. Further activity needs to be undertaken to fully develop the concept and the business case for Government backing.
- 2.2 This grant is being made as the GLA's contribution to the working group to enable it to undertake necessary activities to deliver a further developed concept for the IDRI and a rationale for it in the context of the wider political and funding environment by June 2014.
- 2.3 Intended output: MedCity will deliver a single document outlining the business case for the IDRI in the context of the wider political and funding rationale.
- 2.4 Intended outcome: The rationale will secure to allocation of approximately £75m to £150m towards an IDRI as part of the BIS Science Infrastructure Investment plan, to be announced in the Autumn statement 2014; and the Prime Minister's backing for an IDRI as part of his G7 Dementia Challenge legacy.

3. Equality comments

- 3.1 Change of recipient of funds from UCLP to MedCity does not have any impact protected characteristics (age, disability, gender reassignment, pregnancy and maternity, race, gender, religion or belief, sexual orientation). The expected outcome of the full project would lead to a significant progress in social and clinical care for dementia patients which will have a positive impact on those with disability and in age groups at greater risk.

4. Other considerations

- 4.1 This project is critical to the securing an early win for the MedCity project and the Mayor's Jobs and Growth Strategy's commitment to life sciences.

5. Financial comments

- 5.1 Approval is being sought to grant fund MedCity Limited up to £50,000 on activities relating to the development of a business case for an International Dementia Research Institute based in London.
- 5.2 The total cost of up to £50,000 for this proposal will be funded from the Health and Communities budget for 2014-15 as approved by DD1217 and the Central Programme Panel on the 20th May 2014.
- 5.3 The Health and Communities unit will be responsible for managing this project and ensuring all project activity and expenditure complies with the Authority's Financial Regulations and Contracts & Funding Code.

6. Legal comments

6.1 Legal comments are as per DD1217.

7. Planned delivery approach and next steps

Activity	Timeline
Grant letter to MedCity	1 st September 2014
Support procurement of contract from external project partners	8 th September 2014
Delivery Start Date	8 th September 2014
Draft report presented for comments	30 th September 2014
Delivery End Date	31 st October 2014
Project Closure	30 November 2014

Appendices and supporting papers: DD1217

Public access to information

Information in this form (Part 1) is subject to the Freedom of Information Act 2000 (FOI Act) and will be made available on the GLA website within one working day of approval.

If immediate publication risks compromising the implementation of the decision (for example, to complete a procurement process), it can be deferred until a specific date. Deferral periods should be kept to the shortest length strictly necessary.

Note: This form (Part 1) will either be published within one working day after approval or on the defer date.

Part 1 Deferral:**Is the publication of Part 1 of this approval to be deferred? NO**

If YES, for what reason:

Until what date: (a date is required if deferring)

Part 2 Confidentiality: Only the facts or advice considered to be exempt from disclosure under the FOI Act should be in the separate Part 2 form, together with the legal rationale for non-publication.

Is there a part 2 form –NO

ORIGINATING OFFICER DECLARATION:

Drafting officer
to confirm the
following (✓)

Drafting officer:

Roudie Shafie has drafted this report in accordance with GLA procedures and confirms that the Finance team has commented on this proposal as required, and this decision reflects their comments.

✓

HEAD OF GOVERNANCE AND RESILIENCE:

I confirm that financial and legal implications have been appropriately considered in the preparation of this report.

Signature:

Date: